Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

被引：0

作者：

Bartlett, Nancy L. ^{[1
]}

Sehn, Laurie H. ^{[2
,3
]}

Matasar, Matthew ^{[4
]}

Schuster, Stephen J. ^{[5
]}

Assouline, Sarit ^{[6
]}

Giri, Pratyush ^{[7
]}

Kuruvilla, John ^{[8
]}

Canales, Miguel ^{[9
]}

Dietrich, Sascha ^{[10
]}

Fay, Keith ^{[11
,12
]}

Ku, Matthew ^{[13
]}

Nastoupil, Loretta ^{[14
]}

Wei, Michael C. ^{[15
]}

Yin, Shen ^{[15
]}

To, Iris ^{[15
]}

Huang, Huang ^{[16
]}

Min, Juliana ^{[17
]}

Bolen, Christopher R. ^{[15
]}

Penuel, Elicia ^{[15
]}

Budde, L. Elizabeth ^{[18
]}

机构：

[1] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[2] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Univ British Columbia, Vancouver, BC, Canada

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[6] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[7] Royal Adelaide Hosp, Adelaide, SA, Australia

[8] Princess Margaret Canc Ctr, Toronto, ON, Canada

[9] Hosp Univ La Paz, Madrid, Spain

[10] Heidelberg Univ, Heidelberg, Germany

[11] St Vincents Hosp, Sydney, NSW, Australia

[12] Royal North Shore Hosp, Sydney, NSW, Australia

[13] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[14] MD Anderson Canc Ctr, Houston, TX USA

[15] Genentech Inc, San Francisco, CA USA

[16] Hoffmann La Roche Ltd, Mississauga, ON, Canada

[17] Roche Prod Ltd, Welwyn Garden City, Herts, England

[18] City Hope Natl Med Ctr, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

IBCL; mosunetuzumab; bispecific antibody; relapsed/refractory; follicular lymphoma; Phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-458

引用

页码：S453 / S453

页数：1

共 50 条

[31] Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration directed Phase II study
Fowler, Nathan H.
Samaniego, Felipe
Jurczak, Wojciech
Lech-Maranda, Ewa
Ghosh, Nilanjan
Anz, Bertrand
Patten, Piers
Reeves, James A.
Leslie, Lori A.
Smolewski, Piotr
Chavez, Julio C.
Ghia, Paolo
Tarella, Corrado
Burke, John M.
Sharman, Jeff
Kolibaba, Kathryn
O'Connor, Owen A.
Cheah, Chan Y.
Miskin, Hari P.
Sportelli, Peter
Weiss, Michael S.
Zinzani, Pier Luigi
CANCER RESEARCH, 2019, 79 (13)
[32] RESULTS FROM A PHASE II STUDY INVESTIGATING THE EFFICACY AND SAFETY OF LENALIDOMIDE ORAL MONOTHERAPY IN RELAPSED OR REFRACTORY INDOLENT NOW HODGKIN'S LYMPHOMA
Peter, H. W.
Vose, J. M.
Moore, T. D.
Reeder, C. B.
Cole, C. E.
Justice, G.
Kaplan, H. P.
Voralia, M.
Pietronigro, D.
Takeshita, K.
Ervin-Haynes, A.
Zeldis, J. B.
Witzig, T. E.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 107 - 107
[33] Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
Galsky, M. D.
Retz, M.
Siefker-Radtke, A. O.
Baron, A.
Necchi, A.
Bedke, J.
Plimack, E. R.
Vaena, D.
Grimm, M-O.
Bracarda, S.
Arranz Arija, J.
Pal, S. K.
Ohyama, C.
Saci, A.
Lambert, A.
Krishnan, S.
Azrilevich, A.
Sharma, P.
ANNALS OF ONCOLOGY, 2016, 27
[34] SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study
Brown, Jennifer R.
Hamadani, Mehdi
Arnason, Jon
Karlin, Lionel
Hayslip, John
Wagner-Johnston, Nina
Cartron, Guillaume
Ribrag, Vincent
de Guibert, Sophie
Opat, Stephen
Tilly, Herve
Cannel, Paul
Janssens, Ann
Offner, Fritz
Ganguly, Siddhartha
Ailawadhi, Sikander
Millenson, Michael
Bron, Dominique
Xu, Yi
Ruiz-Soto, Rodrigo
Kersten, Marie Jose
BLOOD, 2013, 122 (21)
[35] Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Primary Analysis of a Phase Ib/II Study
Budde, L. Elizabeth
Olszewski, Adam J.
Assouline, Sarit
Lossos, Izidore S.
Diefenbach, Catherine
Kamdar, Manali
Ghosh, Nilanjan
Modi, Dipenkumar
Sabry, Waleed
Naik, Seema
Mehta, Amitkumar
Nakhoda, Shazia K.
Smith, Stephen D.
Dorritie, Kathleen
Jia, Ting
Pham, Song
Huw, Ling-Yuh
Wu, Hao
To, Iris
Wei, Michael C.
Chavez, Julio C.
BLOOD, 2023, 142
[36] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
BLOOD, 2020, 136
[37] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
[38] CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.
Nastoupil, Loretta J.
Morschhauser, Franck
Scholz, Christian W.
Bishton, Mark
Yoon, Sung-Soo
Giri, Pratyush
Wei, Michael C.
Knapp, Andrea
Li, Chi-Chung
Bottos, Alessia
Li, Haocheng
Purev, Enkhtsetseg
Bartlett, Nancy L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)
Lynch, Ryan C.
Avigdor, Abraham
McKinney, Matthew S.
Paneesha, Shankara
Wahlin, Bjorn
Hrom, John S.
Cunningham, David
Morley, Nicholas
Canales, Miguel
Bastos-Oreiro, Mariana
Belada, David
Devizzi, Liliana
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
BLOOD, 2021, 138
[40] Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with=2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study
Hutchings, Martin
Avigdor, Abraham
Sureda Balari, Anna Maria
Jose Terol, Maria
Bosch, Francesc
Corradini, Paolo
Larsen, Thomas S.
Rueda Dominguez, Antonio
Skarbnik, Alan
Joergensen, Judit Meszaros
Lavie, David
Gurion, Ronit
Zinzani, Pier Luigi
Pinto, Antonio
Cordoba, Raul
Bottos, Alessia
Li, Donghang
Relf, James
De L'Etang, Audrey Filezac
Sellam, Gila
Gritti, Giuseppe
BLOOD, 2023, 142

← 1 2 3 4 5 →